Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998450 · ClinicalTrials.gov registry record · Phase 1
A Study of IMR-687 in Healthy Adult Volunteers
A Phase 1 study, sponsored by Cardurion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02998450 is a Phase 1 study that has completed, run by Cardurion Pharmaceuticals. The registered enrollment target is 66 participants.
The verdict
NCT02998450, a Phase 1 study, has completed, sponsored by Cardurion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects.
Interventions
- DRUG Placebo Oral Capsule
- DRUG IMR-687
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-10-18 |
| Est. Completion | 2017-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02998450
The ClinicalTrials.gov registry entry for NCT02998450 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardurion Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT02998450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02998450 about?
NCT02998450 is a clinical study titled "A Study of IMR-687 in Healthy Adult Volunteers". The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects.
What is the current status of trial NCT02998450?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2016-10-18. Estimated completion is 2017-07-08.
What interventions are being tested in trial NCT02998450?
The interventions under investigation include: Placebo Oral Capsule (DRUG), IMR-687 (DRUG).
Who is sponsoring clinical trial NCT02998450?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.